Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01158300 · ClinicalTrials.gov registry record · Phase 1
PTC299 in Treating Young Patients With Refractory or Recurrent Primary Central Nervous System Tumors
A Phase 1 study of Brain and Central Nervous System Tumors, sponsored by Pediatric Brain Tumor Consortium.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
- 8
- Study locations
NCT01158300: Completed Phase 1 study of Brain and Central Nervous System Tumors, sponsored by Pediatric Brain Tumor Consortium.
NCT01158300 is a Phase 1 study of Brain and Central Nervous System Tumors that has completed, run by Pediatric Brain Tumor Consortium. The registered enrollment target is 28 participants, below the 183-participant average among 45 other Brain and Central Nervous System Tumors trials with a reported enrollment target (85% lower). The trial reports 8 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01158300, a Phase 1 study of Brain and Central Nervous System Tumors, has completed, sponsored by Pediatric Brain Tumor Consortium.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
- 8
- Study locations
Study Summary
RATIONALE: PTC299 may stop the growth of tumor cells by blocking blood flow to the tumor. PURPOSE: This phase I trial is studying the side effects and the best dose of PTC299 in treating young patients with recurrent or refractory primary central nervous system tumors.
Conditions Studied
Interventions
- DRUG VEGF inhibitor PTC299
Study Locations (8)
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
- Children's Hospital of Pittsburgh - Pittsburgh
California
- UCSF Cancer Center and Cancer Research Institute - San Francisco
District of Columbia
- Children's National Medical Center - Washington D.C.
Illinois
- Children's Memorial Hospital - Chicago - Chicago
North Carolina
- Duke Comprehensive Cancer Center - Durham
Tennessee
- St. Jude Children's Research Hospital - Memphis
Texas
- Texas Children's Cancer Center and Hematology Service at Texas Children's Hospital - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2010-11 |
| Est. Completion | 2015-01 |
| Phase | Phase 1 |
What the finished NCT01158300 record still lists
NCT01158300 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 183-participant average among 45 other Brain and Central Nervous System Tumors trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Brain and Central Nervous System Tumors appearing as the primary indexed condition, and to 1 intervention - of which VEGF inhibitor PTC299 is the first listed.
NCT01158300 lists 8 locations in 7 states (Pennsylvania, California, District of Columbia).
Frequently Asked Questions
What is clinical trial NCT01158300 about?
NCT01158300 is a clinical study titled "PTC299 in Treating Young Patients With Refractory or Recurrent Primary Central Nervous System Tumors". RATIONALE: PTC299 may stop the growth of tumor cells by blocking blood flow to the tumor. PURPOSE: This phase I trial is studying the side effects and the best dose of PTC299 in treating young patients with recurrent or refractory primary central nervous system tumors.
What is the current status of trial NCT01158300?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2010-11. Estimated completion is 2015-01.
What conditions does trial NCT01158300 study?
This clinical trial studies the following conditions: Brain and Central Nervous System Tumors.
What interventions are being tested in trial NCT01158300?
The interventions under investigation include: VEGF inhibitor PTC299 (DRUG).
Who is sponsoring clinical trial NCT01158300?
This trial is sponsored by Pediatric Brain Tumor Consortium, which has 27 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01158300 being conducted?
This trial has 8 study locations across California, District of Columbia, Illinois, North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain and Central Nervous System Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01158300's enrollment target sits among peer trials
28 32nd of 45 higher than 13 of 45 other Brain and Central Nervous System Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Brain and Central Nervous System Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Immunotoxin Therapy in Treating Patients With Malignant Glioma
COMPLETED · Phase 1
-
Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment
COMPLETED · Phase 1
-
SCH 66336 in Treating Children With Recurrent or Progressive Brain Tumors
COMPLETED · Phase 1
-
Sirolimus in Treating Patients With Glioblastoma Multiforme
COMPLETED · Phase 1
-
Tetra-O-Methyl Nordihydroguaiaretic Acid in Treating Patients With Recurrent High-Grade Glioma
COMPLETED · Phase 1
-
Mafosfamide in Treating Patients With Progressive or Refractory Meningeal Tumors
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia